Clinical Trials Browser

Phase 2 × capivasertib × 1 year × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02523014 2026-06-02

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Phase 2 Recruiting

Meningioma

NCT03660826 2026-06-02

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2 Active not recruiting

288 enrolled 21 charts

Carcinosarcoma, Carcinoma, Endometrioid

NCT04439123 2026-05-06

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Phase 2 Active not recruiting

35 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT05593497 2026-03-27

SNARE

Phase 2 Recruiting

Prostatic Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT07426822 2026-02-24

SAFE-CAP

Phase 2 Not yet recruiting

Diarrhea, Exanthema

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast Neoplasms